Applied DNA Sciences Inc
APDN5.400USD
-0.109-2.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
34.19MValor de mercado
PerdaP/L TTM
Mais detalhes de Applied DNA Sciences Inc Empresa
Applied DNA Sciences, Inc. is a biotechnology company. The Company is engaged in developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Company operates through three segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. Therapeutic DNA Production Services segment operations consist of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, the development and sale of a proprietary RNAP for use in the production of messenger RNA (mRNA) therapeutics. MDx Testing Service segment operations consist of performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. DNA Tagging and Security Products and Services segment operations consist of the manufacture and detection of DNA for industrial supply chains and security services.
Informações da empresa
Código da empresaAPDN
Nome da EmpresaApplied DNA Sciences Inc
Data de listagemAug 24, 2001
Fundado em2008
CEODr. James A. Hayward, Ph.D.
Número de funcionários46
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 24
Endereço50 Health Sciences Drive
CidadeSTONY BROOK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal11790
Telefone16312408800
Sitehttps://adnas.com/
Código da empresaAPDN
Data de listagemAug 24, 2001
Fundado em2008
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James A. Hayward, Ph.D.
Dr. James A. Hayward, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
President
President
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Ms. Elizabeth M. Schmalz Shaheen
Ms. Elizabeth M. Schmalz Shaheen
Independent Director
Independent Director
--
--
Mr. Sanford (Sandy) Simon
Mr. Sanford (Sandy) Simon
Independent Director
Independent Director
--
--
Mr. Sanjay M. Hurry
Mr. Sanjay M. Hurry
Executive Director - Investor Relations and Corporate Communications
Executive Director - Investor Relations and Corporate Communications
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. James A. Hayward, Ph.D.
Dr. James A. Hayward, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.00
--
Ms. Beth M. Jantzen
Ms. Beth M. Jantzen
Chief Financial Officer
Chief Financial Officer
3.00
--
Ms. Judith Murrah
Ms. Judith Murrah
President
President
3.00
--
Mr. Robert B. (Bob) Catell
Mr. Robert B. (Bob) Catell
Independent Director
Independent Director
2.00
--
Dr. Yacov A. Shamash, Ph.D.
Dr. Yacov A. Shamash, Ph.D.
Independent Director
Independent Director
2.00
--
Mr. Joseph D. Ceccoli
Mr. Joseph D. Ceccoli
Independent Director
Independent Director
1.00
--
Detalhamento da receita
Moeda: USDTempo de atualização: dom, 6 de abr
Moeda: USDTempo de atualização: dom, 6 de abr
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Product and authentication services - Supply chain
722.85K
60.41%
Clinical laboratory testing services (over-time)
324.58K
27.12%
Research and development services
147.44K
12.32%
Clinical laboratory testing services (point-in-time)
1.75K
0.15%
Product and authentication services - Large scale DNA production
0.00
0.00%
Product and authentication services - Asset marking
0.00
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product and authentication services - Supply chain
722.85K
60.41%
Clinical laboratory testing services (over-time)
324.58K
27.12%
Research and development services
147.44K
12.32%
Clinical laboratory testing services (point-in-time)
1.75K
0.15%
Product and authentication services - Large scale DNA production
0.00
0.00%
Product and authentication services - Asset marking
0.00
0.00%
Acionista
Tempo de atualização: sáb, 17 de mai
Tempo de atualização: sáb, 17 de mai
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Estatísticas dos acionistas
Acionista
Proporção
Sabby Management, LLC
1.34%
Altium Capital Management LP
1.25%
S.H.N. Financial Investments Ltd
0.97%
Bigger (Michael)
0.96%
Anson Funds Management LP.
0.88%
Other
94.60%
Tipo
Acionista
Proporção
Investment Advisor/Hedge Fund
2.60%
Corporation
1.77%
Individual Investor
0.99%
Hedge Fund
0.89%
Investment Advisor
0.61%
Research Firm
0.03%
Other
93.12%
Participação acionária institucional
Tempo de atualização: seg, 24 de fev
Tempo de atualização: seg, 24 de fev
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
80
522.82K
38.02%
+37.07K
2024Q4
79
25.60M
46.39%
+1.44M
2024Q3
74
1.08M
9.78%
+703.30K
2024Q2
73
1.19M
10.83%
+424.27K
2024Q1
67
243.32K
209.10%
+86.27K
2023Q4
64
96.98K
13.46%
-84.74K
2023Q3
66
149.12K
21.28%
-82.31K
2023Q2
68
142.47K
21.43%
-74.27K
2023Q1
68
128.77K
20.06%
-84.88K
2022Q4
70
110.09K
17.17%
-81.02K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Sabby Management, LLC
104.48K
9.47%
+19.29K
+22.64%
Dec 31, 2024
Altium Capital Management LP
97.55K
8.84%
--
--
Dec 12, 2024
S.H.N. Financial Investments Ltd
75.50K
6.84%
--
--
Dec 12, 2024
Bigger (Michael)
75.00K
6.79%
--
--
Dec 12, 2024
Anson Funds Management LP.
68.51K
6.21%
--
--
Dec 12, 2024
L1 Capital Global Opportunities Master Fund Ltd.
62.50K
5.66%
--
--
Dec 12, 2024
Grossman (Bruce)
1.67K
0.15%
+1.67K
--
Feb 02, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: há 11 horas
Tempo de atualização: há 11 horas
Nome
Proporção
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Data
Tipo
Proporção
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Mar 12, 2025
Merger
50<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
Apr 22, 2024
Merger
20<1
